BACKGROUND: TCF7L2 gene variants have been associated with increased risk of type 2 diabetes and higher adiposity. Observational studies and short-term trials have suggested that macronutrients may modify these effects. However, to our knowledge, this has yet to be verified in long-term interventions. OBJECTIVE: In a long-term intervention setting, we investigated the effects of TCF7L2 polymorphisms rs7903146 and rs12255372 and dietary total fat on changes in body composition and subsequent glycemic control. DESIGN: Data were analyzed for 591 participants in the Preventing Overweight Using Novel Dietary Strategies (Pounds Lost) trial, which is a 2-y weight-loss randomized clinical trial of diets that differed in macronutrient proportions. Adjusted means for changes in body composition at 6 and 24 mo were obtained for gene main effects and interactions with a low-fat diet (20% from energy) compared with a high-fat diet (40% from energy). Interactions with protein and carbohydrate intakes were also tested. Predicted changes in glycemic control from changes in adiposity were determined by genotype and diet type. RESULTS: Significant interactions were observed for rs12255372 TT (risk genotype) and fat intake for changes in BMI, total fat mass, and trunk fat mass (all P/q < 0.05) at 6 mo, with nonsignificant larger decreases for TT carriers on a low-fat diet. No significant associations were observed at 24 mo or for other macronutrients. Changes in body composition for TT carriers predicted reductions in plasma glucose and insulin only on the low-fat diet. CONCLUSIONS: Individuals with the TCF7L2 rs12255372 risk genotype may reduce body adiposity by consuming a diet lower in total fat. These reductions may induce better glycemic control for such individuals predisposed to type 2 diabetes. The Pounds Lost trial was registered at clinicaltrials.gov as NCT00072995.
RCT Entities:
BACKGROUND:TCF7L2 gene variants have been associated with increased risk of type 2 diabetes and higher adiposity. Observational studies and short-term trials have suggested that macronutrients may modify these effects. However, to our knowledge, this has yet to be verified in long-term interventions. OBJECTIVE: In a long-term intervention setting, we investigated the effects of TCF7L2 polymorphisms rs7903146 and rs12255372 and dietary total fat on changes in body composition and subsequent glycemic control. DESIGN: Data were analyzed for 591 participants in the Preventing Overweight Using Novel Dietary Strategies (Pounds Lost) trial, which is a 2-y weight-loss randomized clinical trial of diets that differed in macronutrient proportions. Adjusted means for changes in body composition at 6 and 24 mo were obtained for gene main effects and interactions with a low-fat diet (20% from energy) compared with a high-fat diet (40% from energy). Interactions with protein and carbohydrate intakes were also tested. Predicted changes in glycemic control from changes in adiposity were determined by genotype and diet type. RESULTS: Significant interactions were observed for rs12255372 TT (risk genotype) and fat intake for changes in BMI, total fat mass, and trunk fat mass (all P/q < 0.05) at 6 mo, with nonsignificant larger decreases for TT carriers on a low-fat diet. No significant associations were observed at 24 mo or for other macronutrients. Changes in body composition for TT carriers predicted reductions in plasma glucose and insulin only on the low-fat diet. CONCLUSIONS: Individuals with the TCF7L2rs12255372 risk genotype may reduce body adiposity by consuming a diet lower in total fat. These reductions may induce better glycemic control for such individuals predisposed to type 2 diabetes. The Pounds Lost trial was registered at clinicaltrials.gov as NCT00072995.
Authors: Struan F A Grant; Gudmar Thorleifsson; Inga Reynisdottir; Rafn Benediktsson; Andrei Manolescu; Jesus Sainz; Agnar Helgason; Hreinn Stefansson; Valur Emilsson; Anna Helgadottir; Unnur Styrkarsdottir; Kristinn P Magnusson; G Bragi Walters; Ebba Palsdottir; Thorbjorg Jonsdottir; Thorunn Gudmundsdottir; Arnaldur Gylfason; Jona Saemundsdottir; Robert L Wilensky; Muredach P Reilly; Daniel J Rader; Yu Bagger; Claus Christiansen; Vilmundur Gudnason; Gunnar Sigurdsson; Unnur Thorsteinsdottir; Jeffrey R Gulcher; Augustine Kong; Kari Stefansson Journal: Nat Genet Date: 2006-01-15 Impact factor: 38.330
Authors: Eva Fisher; Karina Meidtner; Lars Angquist; Claus Holst; Rikke Dalgaard Hansen; Jytte Halkjær; Giovanna Masala; Jane Nautrup Ostergaard; Kim Overvad; Domenico Palli; Karani S Vimaleswaran; Anne Tjønneland; Daphne L van der A; Nicholas J Wareham; Thorkild Ia Sørensen; Ruth Jf Loos; Heiner Boeing Journal: Am J Clin Nutr Date: 2012-05-02 Impact factor: 7.045
Authors: Jose C Florez; Kathleen A Jablonski; Nick Bayley; Toni I Pollin; Paul I W de Bakker; Alan R Shuldiner; William C Knowler; David M Nathan; David Altshuler Journal: N Engl J Med Date: 2006-07-20 Impact factor: 91.245
Authors: Stephanie-May Ruchat; Cathy E Elks; Ruth J F Loos; Marie-Claude Vohl; S John Weisnagel; Tuomo Rankinen; Claude Bouchard; Louis Pérusse Journal: J Nutrigenet Nutrigenomics Date: 2010-03-09
Authors: Kevin M Waters; Daniel O Stram; Mohamed T Hassanein; Loïc Le Marchand; Lynne R Wilkens; Gertraud Maskarinec; Kristine R Monroe; Laurence N Kolonel; David Altshuler; Brian E Henderson; Christopher A Haiman Journal: PLoS Genet Date: 2010-08-26 Impact factor: 5.917
Authors: Yoriko Heianza; Dianjianyi Sun; Tiange Wang; Tao Huang; George A Bray; Frank M Sacks; Lu Qi Journal: Diabetes Date: 2017-06-28 Impact factor: 9.461
Authors: Arkan Abadi; Akram Alyass; Sebastien Robiou du Pont; Ben Bolker; Pardeep Singh; Viswanathan Mohan; Rafael Diaz; James C Engert; Salim Yusuf; Hertzel C Gerstein; Sonia S Anand; David Meyre Journal: Am J Hum Genet Date: 2017-12-07 Impact factor: 11.025
Authors: Yandiswa Y Yako; Jabulisile H Madubedube; Andre P Kengne; Rajiv T Erasmus; Tahir S Pillay; Tandi E Matsha Journal: Afr Health Sci Date: 2015-12 Impact factor: 0.927